PHD1 regulates p53-mediated colorectal cancer chemoresistance

EMBO Molecular Medicine

Volumn 7, Issue 10, 2015, Pages 1350-1365

  Deschoemaeker, Sofie ^a,b   Di Conza, Giusy ^a,b   Lilla, Sergio ^c   Martín Pérez, Rosa ^a,b   Mennerich, Daniela ^d   Boon, Lise ^a,b   Hendrikx, Stefanie ^a,b   Maddocks, Oliver Dk ^c   Marx, Christian ^c,e   Radhakrishnan, Praveen ^f   Prenen, Hans ^g   Schneider, Martin ^f   Myllyharju, Johanna ^d   Kietzmann, Thomas ^d   Vousden, Karen H ^c   Zanivan, Sara ^c   Mazzone, Massimiliano ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF OULU   (Finland)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy resistance; Colorectal cancer; DNA repair; Prolyl hydroxylase domain proteins; Tumor suppressor p53

Indexed keywords

DNA HELICASE; DNA HELICASE XPB; DOXYCYCLINE; FIRTECAN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PHD1 PROTEIN; PHD2 PROTEIN; PHD3 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGLN1 PROTEIN, HUMAN; EGLN2 PROTEIN, HUMAN; EGLN3 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 14;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA REPAIR; EXCISION REPAIR; GENE SILENCING; HCT116 CELL LINE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION; ANIMAL; CELL LINE; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DRUG RESISTANCE; METABOLISM; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 14; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942826593     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505492     Document Type: Article

References (43)

1. Ameln AK, Muschter A, Mamlouk S, Kalucka J, Prade I, Franke K, Rezaei M, Poitz DM, Breier G, Wielockx B (2011) Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFbeta. Cancer Res 71: 3306-3316
2. Aragones J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH et al (2008) Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40: 170-180
3. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805
4. Bohanes P, Labonte MJ, Lenz HJ (2011) A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer 10: 157-164
5. Bouwman P, Jonkers J (2012) The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 12: 587-598
6. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ (2009) Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538
7. Chang YC, Jan KY, Cheng CA, Liao CB, Liu YC (2008) Direct involvement of the tumor suppressor p53 in nucleotide excision repair. DNA Repair 7: 751-761
8. Chen D, Wei L, Yu J, Zhang L (2014) Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin Cancer Res 20: 3472-3484
9. Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (2000) Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 60: 1611-1619
10. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A et al (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54
11. Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V (2003) Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res 63: 8777-8783
12. Ferreira CG, Tolis C, Giaccone G (1999) p53 and chemosensitivity. Ann Oncol 10: 1011-1021
13. Gordon RR, Nelson PS (2012) Cellular senescence and cancer chemotherapy resistance. Drug Resis Update 15: 123-131
14. Hiwatashi Y, Kanno K, Takasaki C, Goryo K, Sato T, Torii S, Sogawa K, Yasumoto K (2011) PHD1 interacts with ATF4 and negatively regulates its transcriptional activity without prolyl hydroxylation. Exp Cell Res 317: 2789-2799
15. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ et al (2009) Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer 101: 1749-1757
16. Kaeser MD, Pebernard S, Iggo RD (2004) Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 279: 7598-7605
17. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609-622
18. Leite de Oliveira R, Deschoemaeker S, Henze AT, Debackere K, Finisguerra V, Takeda Y, Roncal C, Dettori D, Tack E, Jonsson Y et al (2012) Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 22: 263-277
19. Meek DW, Anderson CW (2009) Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1: a000950
20. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737
21. Mikhaylova O, Ignacak ML, Barankiewicz TJ, Harbaugh SV, Yi Y, Maxwell PH, Schneider M, Van Geyte K, Carmeliet P, Revelo MP et al (2008) The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol 28: 2701-2717
22. Mollenhauer M, Kiss J, Dudda J, Kirchberg J, Rahbari N, Radhakrishnan P, Niemietz T, Rausch V, Weitz J, Schneider M (2012) Deficiency of the oxygen sensor PHD1 augments liver regeneration after partial hepatectomy. Langenbecks Arch Surg 397: 1313-1322
23. Moser SC, Bensaddek D, Ortmann B, Maure JF, Mudie S, Blow JJ, Lamond AI, Swedlow JR, Rocha S (2013) PHD1 links cell-cycle progression to oxygen sensing through hydroxylation of the centrosomal protein Cep192. Dev Cell 26: 381-392
24. Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15: 2-8
25. Prenen H, Vecchione L, Van Cutsem E (2013) Role of targeted agents in metastatic colorectal cancer. Target Oncol 8: 83-96
26. Rawluszko AA, Bujnicka KE, Horbacka K, Krokowicz P, Jagodzinski PP (2013) Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer 13: 526
27. Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL (2003) Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 9: 5299-5305
28. Schneider M, Van Geyte K, Fraisl P, Kiss J, Aragones J, Mazzone M, Mairbaurl H, De Bock K, Jeoung NH, Mollenhauer M et al (2010) Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 138: 1143-1154
29. Scholz CC, Cavadas MA, Tambuwala MM, Hams E, Rodriguez J, von Kriegsheim A, Cotter P, Bruning U, Fallon PG, Cheong A et al (2013) Regulation of IL-1beta-induced NF-kappaB by hydroxylases links key hypoxic and inflammatory signaling pathways. Proc Natl Acad Sci USA 110: 18490-18495
30. Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6: 44-55
31. Sermeus A, Michiels C (2011) Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2: e164
32. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23: 1547-1556
33. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106: 3964-3969
34. Takeda Y, Costa S, Delamarre E, Roncal C, de Oliveira RL, Squadrito ML, Finisguerra V, Deschoemaeker S, Bruyere F, Wenes M et al (2011) Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479: 122-126
35. Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, Scholz CC, Fraisl P, Lasitschka F, Mollenhauer M, Saunders SP et al (2010) Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139: 2093-2101
36. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H et al (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15: 390-404
37. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283
38. Wong BW, Kuchnio A, Bruning U, Carmeliet P (2013) Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. Trends Biochem Sci 38: 3-11
39. Xie L, Xiao K, Whalen EJ, Forrester MT, Freeman RS, Fong G, Gygi SP, Lefkowitz RJ, Stamler JS (2009) Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal 2: ra33
40. Xie L, Pi X, Mishra A, Fong G, Peng J, Patterson C (2012) PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response. J Clin Invest 122: 2827-2836
41. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J (2010) Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 138: 606-615
42. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE et al (2009) Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 16: 413-424
43. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM et al (2014) Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev 28: 1429-1444